JP2016540726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540726A5 JP2016540726A5 JP2016519822A JP2016519822A JP2016540726A5 JP 2016540726 A5 JP2016540726 A5 JP 2016540726A5 JP 2016519822 A JP2016519822 A JP 2016519822A JP 2016519822 A JP2016519822 A JP 2016519822A JP 2016540726 A5 JP2016540726 A5 JP 2016540726A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- gene
- pharmaceutical composition
- patient
- tor kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 40
- 108090000623 proteins and genes Proteins 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 27
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 27
- 229940043355 kinase inhibitor Drugs 0.000 claims 24
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 22
- 206010006187 Breast cancer Diseases 0.000 claims 18
- 208000026310 Breast neoplasm Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 15
- 206010064571 Gene mutation Diseases 0.000 claims 8
- 102000054767 gene variant Human genes 0.000 claims 8
- 230000000392 somatic effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 230000004544 DNA amplification Effects 0.000 claims 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 5
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims 5
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 claims 5
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 5
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims 5
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 claims 5
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 claims 5
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 5
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 5
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 4
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims 4
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 101150107888 AKT2 gene Proteins 0.000 claims 2
- 101150045355 akt1 gene Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886785P | 2013-10-04 | 2013-10-04 | |
| US61/886,785 | 2013-10-04 | ||
| US201361907510P | 2013-11-22 | 2013-11-22 | |
| US61/907,510 | 2013-11-22 | ||
| US201462005597P | 2014-05-30 | 2014-05-30 | |
| US62/005,597 | 2014-05-30 | ||
| PCT/US2014/059043 WO2015051251A1 (en) | 2013-10-04 | 2014-10-03 | A tor kinase inhibitor in the prevention or treatment of cancer characterized by gene mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540726A JP2016540726A (ja) | 2016-12-28 |
| JP2016540726A5 true JP2016540726A5 (enExample) | 2017-11-02 |
Family
ID=51869019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519822A Pending JP2016540726A (ja) | 2013-10-04 | 2014-10-03 | 遺伝子突然変異を特徴とする癌の予防又は治療におけるｔｏｒキナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150099754A1 (enExample) |
| EP (1) | EP3052093A1 (enExample) |
| JP (1) | JP2016540726A (enExample) |
| CN (1) | CN105792816A (enExample) |
| MX (1) | MX2016004212A (enExample) |
| WO (1) | WO2015051251A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| CN110592213A (zh) * | 2019-09-02 | 2019-12-20 | 深圳市新合生物医疗科技有限公司 | 预测新抗原负荷和检测基因组突变的基因panel |
| CN115326915A (zh) * | 2022-08-01 | 2022-11-11 | 中央民族大学 | 一种植物组织微阵列maldi-msi高通量分析方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| JP2013508456A (ja) | 2009-10-26 | 2013-03-07 | シグナル ファーマシューティカルズ， エルエルシー | ヘテロアリール化合物の合成方法および精製方法 |
| WO2011112666A1 (en) * | 2010-03-09 | 2011-09-15 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| SG10201912850WA (en) * | 2011-10-19 | 2020-02-27 | Signal Pharm Llc | Treatment Of Cancer With TOR Kinase Inhibitors |
| EP2780469A1 (en) * | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
-
2014
- 2014-10-03 MX MX2016004212A patent/MX2016004212A/es unknown
- 2014-10-03 JP JP2016519822A patent/JP2016540726A/ja active Pending
- 2014-10-03 CN CN201480066619.0A patent/CN105792816A/zh active Pending
- 2014-10-03 EP EP14795888.8A patent/EP3052093A1/en not_active Withdrawn
- 2014-10-03 US US14/505,947 patent/US20150099754A1/en not_active Abandoned
- 2014-10-03 WO PCT/US2014/059043 patent/WO2015051251A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer | |
| Pich et al. | The translational challenges of precision oncology | |
| Marconi et al. | A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? | |
| Nakada et al. | Aberrant signaling pathways in glioma | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| CN106687454B8 (zh) | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 | |
| JP2016540726A5 (enExample) | ||
| JP2016536303A5 (enExample) | ||
| Advani et al. | Precision oncology, signaling, and anticancer agents in cancer therapeutics | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| Park et al. | Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study | |
| Pedersen et al. | Radio-resistance and DNA repair in pediatric diffuse midline gliomas | |
| JP2016529285A5 (enExample) | ||
| JP2017503481A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2019512020A5 (enExample) | ||
| Saunus et al. | Breast cancer brain metastases: clonal evolution in clinical context | |
| JP2019532047A5 (enExample) | ||
| Dall et al. | Interrogating the genomic landscape of uterine leiomyosarcoma: a potential for patient benefit | |
| Senovilla et al. | An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells | |
| Nerone et al. | Beyond PARP inhibitors in advanced breast cancer patients with germline BRCA1/2 mutations: Focus on CDK4/6-inhibitors and data review on other biological therapies | |
| Elshazly et al. | Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors? | |
| Renz et al. | Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI |